GRI Bio, Inc. (GRI): auditor change — GRI Bio dismisses auditor Sadler Gibb, appoints WithumSmith+Brown as new independent accountant.

GRI Bio, Inc.

Audit Committee dismissed Sadler Gibb on April 11, 2025; no disagreements on accounting principles or practices.
Previously reported material weakness in internal control over warrant accounting; no restatements required.
Sadler's reports for FY2024 and FY2023 included a going concern explanatory paragraph but no adverse opinion.
WithumSmith+Brown appointed as independent registered public accounting firm for FY2025.
Sadler furnished a letter to the SEC, filed as Exhibit 16.1, agreeing with the company's disclosures.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

GRI Bio, Inc. engaged WithumSmith+Brown, PC as its auditor.

Action: engagement
Auditor: WithumSmith+Brown, PC

Exact text from the filing

On April 11, 2025, the Audit Committee appointed Withum as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

GRI Bio, Inc. dismissed Sadler Gibb & Associates LLC as its auditor.

Action: dismissal
Auditor: Sadler Gibb & Associates LLC
Successor: WithumSmith+Brown, PC

Exact text from the filing

On April 11, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors of GRI Bio, Inc. (the “Company”) approved the dismissal of Sadler Gibb & Associates LLC (“Sadler”) as the Company’s independent registered public accounting firm.

View on SEC.gov

Browse all auditor changes →

GRI Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001824293-25-000058

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.